Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) ...

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory ...

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to ...

Patients with inflammatory bowel disease (IBD) show high acceptance of adalimumab biosimilars, achieving positive outcomes and clinical remission after switching.

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by ...

Number 5: FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC ...

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

Switching from reference ustekinumab to biosimilar FYB202 maintained comparable efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis. Biosimilar FYB202 or ...